IN PRACTICE
Cystic fibrosis (CF) is a serious autosomal recessive disorder that occurs with varying frequency in all population groups throughout the world, including South Africa (SA). Although CF survival has improved over the past two decades, it remains a life-shortening condition with median survival age now reported in the USA to be ~40 years. [1] Despite early pioneering work relating to the molecular diagnosis of CF in SA, [2] little is known of the current prevalence, clinical spectrum and outcomes of CF in the SA population, which has wide ethnic and genetic diversity. Data from 2005 from the Red Cross War Memorial Children's Hospital CF clinic cohort in Cape Town indicated that the median age of diagnosis and survival age during the preceding 33 years were 6 months and 19.8 years, respectively. [3] Absence of newborn screening, limited access to sweat testing for diagnosis and restricted availability of expensive CF medications (such as inhaled rhDNAse) or lung transplantation are barriers to improving CF survival in SA. Early and accurate diagnosis and understanding the epidemiology of CF in SA are important to improve outcomes and inform health intervention policies.
In order to address the limitations in CF diagnostic capacity and care in SA, the South African Cystic Fibrosis Medical and Scientific Advisory Committee (MSAC) wishes to draw the attention of the readership of the SAMJ to a few important local and international advancements in the field of CF.
The South African Cystic Fibrosis Consensus Guidelines: 5th revision, 2017
The MSAC, in partnership with the South African Cystic Fibrosis Association (SACFA), has revised and published the 5th edition of these guidelines, which comprehensively cover all aspects of CF diagnosis and management appropriate to the SA setting. The guidelines are freely available on the SACFA website (http://www. sacfa.org.za/wp-content/uploads/2017_09_14_CF_Consensus_ Guidelines_2017.pdf). [4] We wish to highlight a few important new concepts that appear in this latest revision.
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diagnosis recommends the following broad classification of CFTR mutations and has adopted the CFTR2 database (https://www. cftr2.org/index.php) as its reference: [5] • CF-causing mutation: results in CF when two abnormal alleles are present in an individual • Mutation of varying clinical consequence (MVCC): a mutation that in combination with a CF-causing mutation or another MVCC may result in CF • Mutation of unknown clinical consequence: not evaluated by CFTR2 • Non-CF-causing mutation.
The recognition that the inheritance of any combination of CFTR mutations will result in a wide spectrum of CF phenotypes is important. Healthcare providers are advised to refer to the CFTR2 database to establish the clinical significance of CFTR mutations that are identified. Consultation with a CF expert and a genetic counsellor is strongly recommended when a CFTR mutation is identified.
Commercially available CFTR genotype panels available in SA can detect up to 50 known CFTR mutations prevalent in the SA population. Included in this panel is p.Phe508del (previously known as ∆F508), the most common mutation in Caucasian and mixed-race people, and c.2988+1G>A (previously known as 3120+1G>A), the most common mutation in black African people. This approach is unsuitable for the SA setting, however, as 79% of black Africans, 55% of individuals of mixed race and 17% of Caucasians will need further molecular testing to confirm a diagnosis of CF. [2] The high proportion of unknown mutations, especially in non-Caucasians with CF, reflects the ethnic and genetic diversity in the SA population. There are few data from the African continent, but a survey identifying disease-causing CF mutations in people of African descent in the Americas found that 55% of alleles still remained unidentified. [6] Next-generation sequencing (NGS) technol ogy, which screens the whole CFTR gene for abnormal alleles, is becoming more accessible and affordable in SA. Although much more powerful than genotyping for detecting CFTR variants, NGS has limitations that relate to interpretation of the clinical significance of detected mutations, many of which can be expected to be novel in SA population. The optimal and most cost-effective approach and strategy to molecular confirmation of CF in SA is under investigation. Further research employing NGS is needed to define the complete spectrum of CFTR variants in the SA population.
Sweat test reference ranges
A sweat chloride concentration >60 mmol/L is the hallmark of typical or classic CF. Abnormal CFTR function in sweat glands manifests as impaired salt (NaCl) reabsorption and is the physiological basis of the sweat test. The recognition of milder or atypical forms of CF associated with mild CFTR mutations and residual CFTR function has led to revision by the International Cystic Fibrosis Foundation of the lower limit of the sweat chloride reference range in the intermediate zone to 30 mmol/L for all ages (previously 40 mmol/L) ( Table 1) . [5] Sweat conductivity is another diagnostic test commonly performed in SA and in some circumstances the only type of 'sweat test' available. It is important that clinicians understand the difference between sweat chloride concentration and sweat conductivity. Sweat conductivity measures the NaCl equivalent concentration of all ionised molecules in sweat, not only chloride. Sweat conductivity is therefore on average 15 -20 mmol/L higher than the equivalent sweat chloride concentration. Sweat conductivity is widely accepted as a good screening test for CF and levels of >50 mmol/L should be followed up with measurement of sweat chloride. In most cases of typical CF, sweat conductivity levels [4] ). (CF = cystic fibrosis; CFTR = cystic fibrosis transmembrane conductance regulator.)
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are conclusively positive. However, in mild or atypical CF, clear reference ranges for conductivity levels are lacking and may lead to misdiagnosis of CF. The MSAC therefore strongly recommends that all laboratory services in SA measure and report only sweat chloride, and use conductivity just as a screening tool. In circumstances where sweat testing is not available, the MSAC recommends measuring faecal elastase as a screening test for pancreatic-insufficient (PI) CF, which occurs in 80 -85% of all CF cases. A normal faecal elastase level therefore does not exclude pancreaticsufficient CF. Where PI CF is confirmed, or there is strong clinical suspicion of CF, collecting a blood sample for DNA testing is recommended. As faecal elastase or genetic results may take several weeks to return, we strongly advise clinicians to empirically commence pancreatic enzyme replacement therapy and other CF-related interventions while waiting for these results if the clinical suspicion of CF is high. Diagnostic algorithms for the diagnosis of CF in SA are shown in Figs 1 and 2 . Furthermore, appropriate sibling and family screening through genetic counselling services is recommended in all people newly diagnosed with CF.
Novel CF treatments
Advances in the molecular biology of the CFTR molecule have identified six distinct classes of CFTR mutations, each associated with different causes and severity of CFTR dysfunction and phenotypic expression. [7] This has led to the development of breakthrough novel therapies that target the underlying CFTR defect at multiple levels, placing CF at the forefront of precision medicine. [7, 8] Clinical trials of the CFTR modulator drugs ivacaftor, which targets the G551D mutation, and lumicafor/tezacaftor, which targets the p.Phe508del mutation, have reported mild to moderate beneficial effects in outcomes including pulmonary function, pulmonary exacerbations and nutrition. [9] [10] [11] The implications for identifying which CFTR mutations each person with CF carries now go beyond simply diagnosis and prognosis and include therapy.
Cautious optimism must be exercised with these new drugs, however. Ivacaftor, indicated for people who carry the G551D mutation (<5% of all people with CF), has shown the best clinical results. Recently published early phase 2 clinical trial results of two new-generation, small-molecule CFTR correctors, VX-445 and VX-659 in triple combination with tezacaftor and ivacaftor ('triple therapy'), show promising results in people with two copies of p.Phe508del. [12, 13] None of these drugs are currently registered and licensed in SA, and until the cost (currently USD300 000 per annum) is substantially reduced, it is unlikely that medical schemes or the public health sector will fund these drugs in the near future. MSAC and the CF community are engaging with international pharma to advocate for affordable access to these new agents in SA.
The South African Cystic Fibrosis Registry Initiative (SACFRI).
In line with international practice, MSAC in partnership with the SACFA launched the SACFRI in April 2018. This initiative aims to document and monitor data relating to the diagnosis and outcomes of all people diagnosed with CF in SA. There is currently little knowledge on the number of individuals with CF in SA, or on their epidemiology or outcomes. Registry data are important and useful for many reasons, including:
• Monitoring overall health outcomes and trends in CF care in order to detect deficits or areas of care that need intervention. By comparing our data with international trends, we can identify gaps in CF care that need attention.
• Keeping accurate statistics in SA will help us advocate for CF care to government and medical aids.
• Planning and conducting research that will benefit the CF community, including identifying individuals who may be eligible for clinical trials of new treatments.
We encourage medical practitioners and members of the CF community to inquire about SACFRI by contacting SACFA or their CF clinic or doctor. Appropriate precautions have been taken to ensure patient confidentiality and protection of medical and personal information, and approval has been obtained from local research ethics committees. Obtaining informed signed consent and assent from people with CF is a requirement for inclusion in the SACFRI database. Although CF is still considered an incurable disorder in 2019, significant advances in its diagnosis, care and treatment mean that CF, previously considered universally fatal in childhood, is now a chronic condition that 
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